Novel Treatments and Targets Under Investigation for Patients With RRMM
November 15th 2023An expert oncologist discusses novel treatments for relapsed/refractory multiple myeloma presented at recent meetings, highlighting a study on elranatamab, a new compound targeting BCMA, and trials including the LINKER-MM1 study on linvoseltamab.
Watch
Managing Adverse Events in Patients With Metastatic Melanoma Receiving First-Line Systemic Therapy
November 15th 2023Hussein Tawbi, MD, PhD, emphasizes the importance of patient education in managing adverse events from the treatment of metastatic melanoma with checkpoint inhibition, discussing symptom recognition, potential side effects, and treatment adjustments while ensuring team accessibility and patient communication.
Watch
MARIPOSA-2: Amivantamab + Lazertinib + Chemotherapy in EGFR-Mutated Advanced NSCLC
November 14th 2023Shared insight from key opinion leaders on results from MARIPOSA-2 and the role of amivantamab plus lazertinib and chemotherapy in patients with advanced NSCLC following progression on osimertinib.
Watch
Updates from PAPILLON: 1L Amivantamab + Chemotherapy in Advanced NSCLC
November 14th 2023Oncology Brothers Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Alexander Spira, MD, PhD, FACP, to review data from PAPILLON, which combined amivantamab and chemotherapy as frontline treatment for patients with advanced NSCLC.
Watch
Advice for Oncologists and Next Steps for the CLEAR Trial in RCC
November 12th 2023Viktor Grünwald, MD, PhD, discusses what findings from the post hoc analysis of the CLEAR trial of lenvatinib plus pembrolizumab vs sunitinib for patients with renal cell carcinoma mean for community oncologists.
Watch
Treatment Goals for Patients With Myelofibrosis
November 10th 2023Treatment goals for patients with myelofibrosis include prolonged survival and improved quality of life, with decision-making incorporating risk level, transplant eligibility, toxicity, and clinical trial data to select among the available JAK inhibitors.
Watch
KEYNOTE-756: Pembrolizumab Plus Chemo in Early-Stage ER+/HER2- Breast Cancer
November 9th 2023Erika P. Hamilton, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from KEYNOTE-756 investigating pembrolizumab plus chemotherapy in early-stage ER+/HER2- breast cancer.
Watch
Case Presentation: A 76-Year-Old Woman With Newly-Diagnosed Myelofibrosis (MF)
November 8th 2023Anthony Hunter, MD, presents the case of a 76-year-old woman with newly diagnosed primary myelofibrosis with a JAK2 mutation, for which he recommended treatment with momelotinib due to her moderate anemia and refusal of transplant.
Watch
Key Trial Data in the Frontline Treatment of Metastatic Melanoma
November 8th 2023Over the past decade, the frontline treatment landscape for metastatic melanoma has evolved with studies like CheckMate-067 and KEYNOTE-006 highlighting the superiority of PD-1-based therapies over ipilimumab, and recent trials introducing new combination treatments.
Watch
Optimal Sequencing in Patients With RRMM Previously Treated With a BCMA-Targeted Therapy
November 8th 2023Rafael Fonseca, MD, discusses the sequencing of CAR-T and bispecific antibodies in patients with relapsed/refractory multiple myeloma and tailoring treatment based on prior medical history for elderly and frail individuals.
Watch